<?xml version="1.0" encoding="UTF-8"?>
<p>Immune checkpoint inhibitors as a new anti-tumor drug have completely changed the treatment mode for kidney cancer. However, the objective response rate is only about 25% and complete remission rate is only about 1% (
 <xref rid="B9" ref-type="bibr">9</xref>). Therefore, a combination treatment strategy is the focus of current research. Research on the combination of targeted chemotherapy drugs and combined immunotherapy is prevalent in the literature. However, few studies on the combination of targeting PD-1 and using CIK cells exist.
</p>
